Sequential Afatinib and Osimertinib in Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Final Analysis of the GioTag Study
Aim: Final overall survival (OS) and time on treatment analysis of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib and osimertinib. Patients & methods: Patients (n = 203) had T790M-positive disease following first-line afatinib and started osimertinib treatment ≥10 months before data entry. Primary outcome was time on treatment; OS analysis was exploratory. Results: Median time on treatment with afatinib and osimertinib was 27.7 months (90% CI: 26.7–29.9). Median OS was 37.6 months (90% CI: 35.5–41.3); median OS was 41.6 and 44.8 months in Del19-positive patients and Asian patients, respectively. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib was associated with encouraging outcomes in patients with EGFR mutation-positive NSCLC, especially in Del19-positive patients and Asian patients. Clinical Trial Registration: NCT03370770 (ClinicalTrials.gov) A PDF version of this infographic is available as supplemental material.
Authors
- Desirée Hao (ORCID: https://orcid.org/0000-0003-1727-1205)
- Cheng Yang (ORCID: https://orcid.org/0000-0002-3082-4890)
- Ross Andrew Soo (ORCID: https://orcid.org/0000-0002-3053-3997)
- Alessandro Morabito (ORCID: https://orcid.org/0000-0002-1319-9608)
- Tanja Čufer (ORCID: https://orcid.org/0000-0002-4417-7161)
- Angela Märten
- Hochmair Maximilian J.
- Balazs Halmos (ORCID: https://orcid.org/0000-0001-7548-8360)
- James C. H. Yang
- Rasim Gucalp
Publication Details
- Journal
- Figshare
- Published
- 2026-11-12
- DOI
- https://doi.org/10.6084/m9.figshare.34998058
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00